BRTX vs RGEN vs ICLR vs TECH vs TMO

For growth investors, BioRestorative Therapies, Inc.

(BRTX) is the stronger pick with 175. 0% revenue growth year-over-year, versus 2. 0% for ICON Public Limited Company (ICLR). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Repligen Corporation at 147. 0x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ICON Public Limited Company wins at 1. 50x versus Thermo Fisher Scientific Inc. 's 9. 05x — a reasonable growth-adjusted valuation.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 8%, compared to -99. 4% for BioRestorative Therapies, Inc. (BRTX). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus BRTX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 1. 10β versus BioRestorative Therapies, Inc. 's 2. 21β — meaning BRTX is approximately 101% more volatile than TMO relative to the S&P 500. On balance sheet safety, Bio-Techne Corporation (TECH) carries a lower debt/equity ratio of 23% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioRestorative Therapies, Inc.

(BRTX) is pulling ahead at 175. 0% versus 2. 0% for ICON Public Limited Company (ICLR). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -56. 2% for Bio-Techne Corporation. Over a 3-year CAGR, BRTX leads at 105. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus -22. 4% for BioRestorative Therapies, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -28. 8% for BRTX. At the gross margin level — before operating expenses — BRTX leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ICON Public Limited Company (ICLR) is the more undervalued stock at a PEG of 1. 50x versus Thermo Fisher Scientific Inc. 's 9. 05x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 5x forward P/E versus 64. 3x for Repligen Corporation — 53. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

In this comparison, TECH (0.

6% yield), TMO (0. 4% yield) pay a dividend. BRTX, RGEN, ICLR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

6% yield, +112. 5% 10Y return). BioRestorative Therapies, Inc. (BRTX) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECH: +112. 5%, BRTX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BRTX is a small-cap high-growth stock; RGEN is a small-cap high-growth stock; ICLR is a small-cap deep-value stock; TECH is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock. TECH pays a dividend while BRTX, RGEN, ICLR, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.